Table 1 Baseline characteristics and treatment variables, and baseline primary outcome measures

Animals (n =)

8

8

8

–

Weight (kg)

51.5 (5.2)

50.9 (7.7)

52.3 (6.3)

0.75

Haemorrhage time (min)

68 (15)

74 (16)

78 (14)

0.49

Total haemorrhage (mL)^b

1427 (177)

1630 (358)

1694 (328)

0.067

Haemorrhage (%TBV)

41.4 (5.2)

46.8 (6.2)

48.5 (9.5)

0.145

Total resus volume (L)

3.64 (1.63)

4.07 (0.54)

3.16 (0.89)

0.28

Resus/haem volume ratio

2.5 (0.9)

2.6 (0.4)

1.9 (0.5)

0.117

Resus rate (mL/kg/h)

17.5 (6.9)

21.0 (3.3)

15.2 (4.0)

0.087

NorAd use per group

4/8

4/8

3/8

–

NorAd, total dose (mcg/kg)

0.0318 (0.0149)

0.0228 (0.0134)

0.0100 (0.0009)

0.87

Other vasopressor use

Dopamine: 1/8

Metaraminol: 1/8

0/8

–

MAP (mmHg)

66–95

84 (9)

84 (8)

92 (23)

0.50

Cardiac index (L/min/m²)

1.9–6.5

4.2 (1.6)

3.1 (0.7)

3.8 (0.6)

0.144

Heart rate (beats/min)

58–128

111 (30)

94 (20)

86 (18)

0.048

SVRI (dynes*s/cm⁵/m²)

800–3200

1645 (789)

2069 (436)

1875 (403)

0.137

PaO₂/FiO₂ ratio

229–543

338 (77)

345 (95)

425 (90)

0.112

Hb, post-adrenaline (g/L)

94–14.8

112 (14)

123 (16)

125 (18)

0.26

SvO₂ (%)

57–85

71 (9)

74 (8)

72 (7)

0.76

Brain StO₂ (%)

51–88

76 (10)

72 (8)

67 (8)

0.132

Muscle StO₂ (%)

56–78

62 (10)

69 (9)

66 (6)

0.27

Arterial lactate (mM)

0.4–1.9

1.7 (2.1)

0.7 (0.2)

1.2 (1.0)

0.192

Base excess (mM)

− 4.7 to  + 5.7

1.8 (2.8)

2.3 (2.5)

0.6 (3.3)

0.92